Merck Serono, the biopharmaceutical business of Merck, today announced
the expansion of its R&D facility in Darmstadt, Germany. Merck is
investing € 65 million in a new laboratory building that will span more
than 16,000 square meters and accommodate approximately 200 current
employees whose focus will be accelerating innovation in R&D.
At the cornerstone laying ceremony in Darmstadt today, Belén Garijo, Executive Board Member of Merck and CEO Healthcare, and Kai Beckmann, Member of the Executive Board of Merck and besides others with responsibility for Site Operations in Darmstadt, emphasized the significance of this expansion and investment into innovation as a driver of future growth for Merck.
At the cornerstone laying ceremony in Darmstadt today, Belén Garijo, Executive Board Member of Merck and CEO Healthcare, and Kai Beckmann, Member of the Executive Board of Merck and besides others with responsibility for Site Operations in Darmstadt, emphasized the significance of this expansion and investment into innovation as a driver of future growth for Merck.
The new building will unite different functions within R&D Discovery
Technologies at Merck Serono, including Molecular Pharmacology,
Medicinal Chemistry, Computational Chemistry, Molecular Interactions and
Biophysics, Protein Engineering and Antibody Technologies, and Protein
and Cell Sciences.
The research building, when complete in fall of 2017, will be located within the new "Pharma Square" on the Merck campus in Darmstadt. Merck is thus uniting a significant part of its R&D activities in a single area, creating ideal conditions for the advancement of its biopharmaceutical pipeline.
With approximately 2,000 scientific and clinical development professionals working across four R&D hubs - Darmstadt, Germany, the largest R&D site; Boston, US; Tokyo, Japan; and Beijing, China - Merck Serono endeavors to make a meaningful difference in the lives of people with serious medical needs. The core areas of R&D focus for Merck Serono are oncology, immuno-oncology, and immunology.
The research building, when complete in fall of 2017, will be located within the new "Pharma Square" on the Merck campus in Darmstadt. Merck is thus uniting a significant part of its R&D activities in a single area, creating ideal conditions for the advancement of its biopharmaceutical pipeline.
With approximately 2,000 scientific and clinical development professionals working across four R&D hubs - Darmstadt, Germany, the largest R&D site; Boston, US; Tokyo, Japan; and Beijing, China - Merck Serono endeavors to make a meaningful difference in the lives of people with serious medical needs. The core areas of R&D focus for Merck Serono are oncology, immuno-oncology, and immunology.
